Skip to main content
PMC home page
The Indian Journal of Surgery logoLink to The Indian Journal of Surgery
. 2010 Feb 5;72(1):27–31. doi: 10.1007/s12262-010-0005-8

Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers

Shyam S Jaiswal 1,✉, R P S Gambhir 1, Amit Agrawal 1, S Harish 1
PMCID: PMC3452554  PMID: 23133200

Abstract

Background

Lower extremity ulcers are a serious complication of diabetes mellitus (DM). These ulcers show decreased angiogenic response and production of growth factors. Recombinant human platelet derived growth factor (rhPDGF) has been found to decrease the time to healing. This study was conducted to evaluate its efficacy in the treatment of diabetic foot ulcers.

Methods

A total of 50 patients with type 1 or type 2 DM and chronic ulcers, of at least 4 weeks duration, were studied. They were randomised into two groups, of 25 patients each. The patients in group ‘A’ (test group) received treatment with topical application of rhPDGF gel and those in group ‘B’ (control group) were treated with local application of KY Jelly as a placebo. A standardised regimen of good wound care was provided to both groups. Healing or reduction in size of the wound, over a period of 10 weeks after commencement of treatment was recorded.

Results

The mean age of the patients was 49.9 years in the control group and 56.2 years in test group. The median duration of ulcer at time of enrolment in the study was 6 weeks in control and 5 weeks in test group. Fifteen ulcers in control group belonged to IAET (International Association of Enterostomal Therapy) class III and 10 ulcers to class IV where as 16 ulcers were in IAET class III and 9 ulcers in IAET class IV in the test group. The mean size of the wounds was 26.5 ± 2.5 cm2 in control group and 29.9 ± 3.4 cm2 in test group. All patients tolerated the test medication well. At the end of 10 weeks, 18 (72%) ulcers had healed in control group and 15 (60%) in test group (p > 0.05). Three ulcers in control group showed >75% reduction in size compared to 2 in the test group (p > 0.05).

Conclusion

This study did not show any statistically significant improvement in ulcer healing rates after the use of topically applied rhPDGF.

Keywords: Chronic diabetic foot ulcer, Recombinant human platelet derived growth factor (rhPDGF)

Full Text

The Full Text of this article is available as a PDF (248.1 KB).

References

  • 1.Macfarlane I.A., Bliss M., Jackson J.G.L., William G. The history of diabetes mellitus. In: Pickup J.C., Williams G., editors. Textbook of Diabetes. Oxford: Blackwell Science; 1991. pp. 1–21. [Google Scholar]
  • 2.Aboderin I. Life course perspectives on coronary heart disease, stroke and diabetes: key issues and implications for policy and research. WHO: Geneva; 2001. p. 5. [Google Scholar]
  • 3.National diabetes fact sheet: general information and national estimates on diabetes in the United States. Atlanta, GA: US Dept of Health and Human Services, Centers for Disease control and Prevention; 2002. [Google Scholar]
  • 4.Powers Alvin C (2005) Diabetes mellitus. In: Harrison’s Principles of Internal Medicine. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (Eds.), 16th edition, McGraw-Hill pp. 2152–2180
  • 5.Eugelgan M.M., Geiss L.S., Saaddine J.B. The evolving diabetes burden in the United States. Ann Intern Med. 2004;140:945–950. doi: 10.7326/0003-4819-140-11-200406010-00035. [DOI] [PubMed] [Google Scholar]
  • 6.Moulik P.K., Mtonga R., Gill G.V. Amputation and mortality in new onset diabetic foot ulcers stratified by etiology. Diabetes Care. 2003;26:491–494. doi: 10.2337/diacare.26.2.491. [DOI] [PubMed] [Google Scholar]
  • 7.Brem H., Sheehan P., Boulton A.J.M. Protocol for treatment of diabetic foot ulcers. Am J Surg. 2004;187(5A):1S–10S. doi: 10.1016/S0002-9610(03)00299-X. [DOI] [PubMed] [Google Scholar]
  • 8.Steed D.L. The role of growth factors is wound healing. Surg Clin North Am. 1997;77:575–586. doi: 10.1016/S0039-6109(05)70569-7. [DOI] [PubMed] [Google Scholar]
  • 9.Nagai M.K., Embil J.M. Becaplermin: Recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers. Expert Opin Biol Ther. 2002;2:211–218. doi: 10.1517/14712598.2.2.211. [DOI] [PubMed] [Google Scholar]
  • 10.Wiemen T.J., Smiell J.M., Su Y. Efficacy and safety of a Topical Gel formulation of Recombinant Human Platelet Derived Growth Factor BB (Becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes Care. 1998;21:5. doi: 10.2337/diacare.21.5.822. [DOI] [PubMed] [Google Scholar]
  • 11.Boulton A.J.M., Armstrong D.G. The diabetic foot. In: Fonseca V.A., editor. Clinical Diabetes: Translating Research into Practice. 1st edition. Saunders: Elsevier; 2006. pp. 179–195. [Google Scholar]
  • 12.International Association of Enterostomal Therapists Dermal wounds: Pressure sores: Philosophy of the IAET. Journal of Enterostomal Therapy. 1988;15:4–17. [PubMed] [Google Scholar]
  • 13.Shobhana R., Rama Rao P., Lavanya A., Viswanathan V., Ramachandran A. Cost burden to diabetic patients with foot complications — a study from southern India. JAPI. 2000;48:1147–1150. [PubMed] [Google Scholar]
  • 14.Koveker G.B. Growth factors in clinical practice. Int J Clin Pract. 2000;54(9):590–593. [PubMed] [Google Scholar]
  • 15.Papanas N., Maltezos E. Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises? Int J Low Extrem wounds. 2007;6(1):37–53. doi: 10.1177/1534734606298416. [DOI] [PubMed] [Google Scholar]
  • 16.Steed D.L. Clinical evaluation of recombinant human platelet derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg. 2006;117:143S–149S. doi: 10.1097/01.prs.0000222526.21512.4c. [DOI] [PubMed] [Google Scholar]
  • 17.Margolis D.J., Bartus C., Hoffstad O., Berlin J.A. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. Wound Repair Regen. 2005;13(6):531–536. doi: 10.1111/j.1524-475X.2005.00074.x. [DOI] [PubMed] [Google Scholar]
  • 18.Harrison-Balestra C., Eaglstein W.H., Falabela A.F., Kirsner R.S. Recombinant human platelet-derived growth factor for refractory nondiabetic ulcers: A retrospective series. Dermatol Surg. 2002;28(8):755–759. doi: 10.1046/j.1524-4725.2002.02004.x. [DOI] [PubMed] [Google Scholar]
  • 19.Cohen M.A., Eaglstein W.H. Recombinant human platelet-derived growth factor gal speeds healing of acute full-thickness punch biopsy wounds. J Am Acad Dermal. 2001;45(6):857–862. doi: 10.1067/mjd.2001.117721. [DOI] [PubMed] [Google Scholar]
  • 20.Smiell J.M., Wieman T.J., Steed D.L., Perry B.H., Sampson A.R., Schwab B.H. Efficacy and safety of becaplermin (recombinant human platelet derived growth factor-BB) in patients with non-healing, lower extremity diabetic ulcers: A combined analysis of four randomized trials. Wound Repair Regen. 1999;7:335–346. doi: 10.1046/j.1524-475X.1999.00335.x. [DOI] [PubMed] [Google Scholar]
  • 21.Schaffer M., Coerper S., Becker H.D. Gene therapy in diabetic foot. Kongressbd Dtsch Ges Chir Kongr. 2001;118:825–828. [PubMed] [Google Scholar]
  • 22.Loot M.A., Kenter S.B., Au F.L. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol. 2002;81(3):153–160. doi: 10.1078/0171-9335-00228. [DOI] [PubMed] [Google Scholar]

Articles from The Indian Journal of Surgery are provided here courtesy of Springer

RESOURCES